What is Folotyn, and how does it work?
Folotyn (pralatrexate injection) is an antineoplastic (anti-cancer) drug used to treat T-cell lymphoma that has spread throughout the body. Folotyn is given for relapsed T-cell lymphoma, or after other medications have been tried without successful treatment.
What are the side effects of Folotyn?
Common side effects of Folotyn include:
- redness or sores of the mouth/lips/throat
- nausea
- vomiting
- loss of appetite
- diarrhea
- constipation
- tired feeling
- fatigue
- cough
- swelling
- mild rash or itching
- constipation
- fever
- swelling
- anemia
- low platelet count.
Serious skin reactions can occur. Tell your doctor if you develop rash, peeling, sores or blisters on the skin while using Folotyn. Tell your doctor if you have unlikely but serious side effects of Folotyn including:
- signs of infection (such as fever, cough, sore throat, chills),
- easy bleeding or bruising,
- dehydration,
- feeling weak,
- looking pale, or
- shortness of breath.
What is the dosage for Folotyn?
Important Dosing Information
Pretreatment Vitamin Supplementation
Instruct patients to take folic acid 1 to 1.25 mg orally once daily beginning 10 days before the first dose of Folotyn. Continue folic acid during treatment with Folotyn and for 30 days after the last dose.
Vitamin B12
Administer vitamin B12 1 mg intramuscularly within 10 weeks prior to the first dose of Folotyn and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn.
Recommended Dosage
The recommended dosage of Folotyn is 30 mg/m² intravenously over 3-5 minutes once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity.
Dosage Modifications For Renal Impairment And End Stage Renal Disease
- Severe renal impairment (eGFR 15 to 29 mL/min/1.73 m² by MDRD): Reduce the Folotyn dose to 15 mg/m².
- End stage renal disease (ESRD: eGFR less than 15 mL/min/1.73 m² by MDRD) with or without dialysis: Avoid administration. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the Folotyn dose based on adverse reactions.
Monitoring And Dosage Modifications For Adverse Reactions
Monitoring
Monitor complete blood cell counts and severity of mucositis at baseline and weekly. Perform serum chemistry tests, including renal and hepatic function, prior to the start of the first and fourth dose of each cycle.
Recommended Dosage Modifications
Do not administer Folotyn until:
- Mucositis Grade 1 or less.
- Platelet of 100,000/mcL or greater for first dose and 50,000/mcL or greater for all subsequent doses.
- Absolute neutrophil count (ANC) of 1,000/mcL or greater. Dosage modifications for adverse reactions are provided in Tables 1, 2, and 3.
Table 1 : Folotyn Dosage Modifications for Mucositis
Mucositis Gradea on Day of Treatment | Action | Recommended Dose upon Recovery to Grade 0 or 1 | |
Patients Without Severe Renal Impairment | Patients with Severe Renal Impairment | ||
Grade 2 | Omit dose | Continue prior dose | Continue prior dose |
Grade 2 recurrence | Omit dose | 20 mg/m² | 10 g/m² |
Grade 3 | Omit dose | 20 mg/m² | 10 g/m² |
Grade 4 | Stop therapy | ||
a Based National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) |
Table 2 : Folotyn Dosage Modifications for Myelosuppression
Blood Count on Day of Treatment | Duration of Toxicity | Action | Recommended Dose Upon Recovery | |
Patients Without Severe Renal Impairment | Patients with Severe Renal Impairment | |||
Platelet less than 50,000/mcL | 1 week | Omit dose | Continue prior dose | Continue prior dose |
2 weeks | Omit dose | 20 mg/m² | 10 mg/m² | |
3 weeks | Stop therapy | |||
ANC 500 to 1,000/mcL and no fever | 1 week | Omit dose | Continue prior dose | Continue prior dose |
ANC 500 to 1,000/mcL with fever or ANC less than 500/mcL | 1 week | Omit dose, give G-CSF or GM-CSF | Continue prior dose with G-CSF or GM-CSF | Continue prior dose with G-CSF or GM-CSF support |
2 weeks or recurrence | Omit dose, give G-CSF or GM-CSF | 20 mg/m² with G-CSF or GM-CSF | 10 mg/m² with G-CSF or GM-CSF | |
3 weeks or nd 2 recurrence | Stop therapy | |||
G-CSF=granulocyte colony-stimulating factor; GM-CSF=granulocyte macrophage colony-stimulating factor |
Table 3 : Folotyn Dosage Modifications for All Other Adverse Reactions
Toxicity Gradea on Day of Treatment | Action | Recommended Dose upon Recovery to Grade 2 or Lower | |
Patients Without Severe Renal Impairment | Patients with Severe Renal Impairment | ||
Grade 3 | Omit dose | 20 mg/m² | 10 mg/m² |
Grade 4 | Stop therapy | ||
a Based on NCI CTCAE version 3.0 |

SLIDESHOW
Skin Cancer Symptoms, Types, Images See SlideshowWhat drugs interact with Folotyn?
Effects Of Other Drugs On Folotyn
Coadministration of Folotyn with probenecid increased pralatrexate plasma concentrations, which may increase the risk of adverse reactions. Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions.
Is Folotyn safe to use while pregnant or breastfeeding?
- Based on findings from animal studies and its mechanism of action, Folotyn can cause fetal harm when administered to a pregnant woman.
- There are insufficient data on Folotyn use in pregnant women to evaluate for a drug-associated risk.
- Folotyn was embryotoxic and fetotoxic in rats and rabbits when administered during organogenesis at doses about 1.2% (0.012 times) of the clinical dose on a mg/m² basis.
- Advise pregnant women of the potential risk to a fetus.
- There is no data on the presence of pralatrexate in human milk or its effects on the breastfed child or milk production.
- Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with Folotyn and for 1 week after the last dose.
Latest Cancer News
Daily Health News
Summary
Folotyn (pralatrexate injection) is an antineoplastic (anti-cancer) drug used to treat T-cell lymphoma that has spread throughout the body. Folotyn is given for relapsed T-cell lymphoma, or after other medications have been tried without successful treatment.
Multimedia: Slideshows, Images & Quizzes
Related Disease Conditions
-
Non-Hodgkin's Lymphomas
Second Source article from Government
-
Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma. It is not known what causes MCL. MCL signs and symptoms include fever, enlarged spleen and liver, fatigue, and weight loss. Treatment of MCL incorporates radiotherapy and chemotherapy. MCL has a poor prognosis as it typically is diagnosed in a late stage.
-
Can Lymphoma Be Completely Cured?
Lymphomas are considered to be a treatable form of cancer if detected early. The overall 5-year survival rate for non-Hodgkin lymphoma (NHL) is 62%, whereas the 5-year survival rate for Hodgkin lymphoma is 92% if detected early.
-
What Is Non-Hodgkin's Lymphoma?
Non-Hodgkin's lymphoma (NHL) is cancer of the lymphatic system, a vital part of the body's immune system. Symptoms include swollen lymph nodes, fever, night sweats, coughing, weakness, chest pain, unexplained weight loss, and abdominal pain.
-
Hodgkin's vs. Non-Hodgkin's Lymphoma
Both Hodgkin's disease (sometimes referred to as Hodgkin's lymphoma) and non-Hodgkin's lymphoma are cancers that originate in a type of white blood cell known as a lymphocyte, an important component of the body's immune system.
-
What Is Burkitt Lymphoma?
There are multiple types of Burkitt lymphoma. Burkitt lymphomas are types of non-Hodgkin's lymphoma that affect the bone marrow and central nervous system. Symptoms of Burkitt lymphoma may include nausea, vomiting, headache, fatigue, enlarged lymph nodes, and many other symptoms. Diagnosis involves lab testing, imaging studies, patient history, and cytogenic evaluation. There are multiple staging systems used to stage Burkitt lymphoma. Treatment consists of chemotherapy. The prognosis tends to be more favorable in children than in adults.
-
What Is the Main Cause of Primary Lymphoma of Bone?
Primary lymphoma of bone (PLB) is a rare type of cancer that starts in the bone instead of the lymph nodes. PLB accounts for less than 5% of all bone tumors. PLB is also known as reticulum cell sarcoma, malignant lymphoma of bone or osteolymphoma, and it is a type of non-Hodgkin’s lymphoma. Pain is the most common symptom of PLB.
-
How Bad Is Lymphoma Cancer Of Bone?
Lymphoma is a cancer of infection-fighting cells (lymphocytes), white blood cells of the immune system. These cells are normally found in the lymph nodes, spleen, thymus, and bone marrow.
-
How Do You Get Non-Hodgkin’s Lymphoma?
Non-Hodgkin lymphoma (NHL) is cancer that affects the lymphatic system, a part of the body’s immune system. The lymphatic system helps in filtering foreign cells and microorganisms. The lymphatic system is comprised of lymph fluid, lymph nodes, tonsils, thymus, and the spleen.
Treatment & Diagnosis
Medications & Supplements
Health Solutions From Our Sponsors

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.